Status:
RECRUITING
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Lymphoma
Leukemia
Eligibility:
All Genders
5+ years
Brief Summary
Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about ...
Detailed Description
Background: * Chimeric antigen receptor (CAR) T-cell immunotherapy has rapidly emerged as a successful and breakthrough treatment in pediatric and adult hematologic malignancies. However, significant...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Participants with disease
- Participants are diagnosed with relapsed/refractory leukemias or lymphomas, and are scheduled to receive CAR T-cell treatment in one of the enrolling sites
- For participants enrolled on a CAR T-cell treatment protocol, data sharing for the purposes of this study must be allowed.
- Age \>= 5 and \<=35 years old
- Participant must have an eligible caregiver (informant) who is willing to complete assessments about the participant of this study
- Participants (\<18 years, or \>=18 years if needed) must have an eligible caregiver to assist with setting up an appropriate test environment for the remote evaluations
- Participant must be able to speak and understand English or Spanish
- Participants must have access to a computer or tablet with a camera and an internet connection
- Participant or parent/guardian must be able to understand and willing to sign a written consent document
- Caregivers (informants)
- Participants must be able to speak and read in English or Spanish
- Participants who are caregivers for participants with disease addressed above
- Age \>= 18 years old
- Participants must have access to a computer or tablet
- Participants (of children \<18 years, or \>18 years if needed) must be willing to help set up an appropriate test environment for the remote evaluations
- Participant is able to understand and willing to sign a written consent document
- EXCLUSION CRITERIA:
- Participants with disease who have a pre-existing global intellectual disability (e.g., Down Syndrome)
Exclusion
Key Trial Info
Start Date :
June 23 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05237986
Start Date
June 23 2025
End Date
April 30 2027
Last Update
January 9 2026
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Children s Hospital of Los Angeles
Los Angeles, California, United States, 90027
2
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
3
Seattle Children s Hospital
Seattle, Washington, United States, 98105